Weight Management Medication Posted or Updated on 22 Aug 2025

Following approval by NICE, tirzepatide (Mounjaro®) will be available on the NHS for eligible patients who meet the strict, nationally-set, criteria.  

The current criteria is that patients are those with a BMI of 40 or higher, and with four or more of the qualifying comorbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) will be eligible for assessment to identify their suitability for Mounjaro. Anyone not meeting these criteria will not be eligible for assessment in the first year of the drug being available.  

Please do not contact your GP; if you are eligible to be assessed you will be contacted over the coming months and invited to attend an appointment for assessment. Those with the greatest clinical need will be contacted first, so this may mean you have to wait a little longer for an appointment, however it is our intention that anyone who meets the above criteria will have been invited for an assessment over the next 12 months.

More information here